论文部分内容阅读
目的:研究n-3脂肪酸对非血液透析的终末期肾脏病(ESRD)合并心血管疾病患者体内甲基化精氨酸水平的影响,进一步探讨n-3脂肪酸在ESRD患者发挥心血管保护作用的机制。方法:根据入选标准随机选择ESRD(以慢性肾脏疾病5期作为代表)合并心血管疾病的患者114名,在标准饮食的基础上随机选取57名给予1.4 g n-3脂肪酸干预(实验组),其余给予等量的橄榄油干预(对照组)。实验前后酶联免疫法(ELISA)检测各组患者循环中非对称性二甲基精氨酸(ADMA)、对称性二甲基精氨酸(SDMA)和L精氨酸的水平,气液色谱法检测血浆n-3脂肪酸中二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)的浓度。结果:给予n-3脂肪酸干预3月后ADMA、SDMA和L精氨酸水平未见明显改变。研究对象血清中EPA和DHA的水平较实验前显著升高。结论:n-3脂肪酸对非血透的ESRD合并心血管疾病循环中甲基化精氨酸的水平没有影响,n-3脂肪酸并未通过减少ESRD合并心血管疾病患者循环中甲基化精氨酸的水平而起到心血管的保护作用。
Objective: To investigate the effect of n-3 fatty acid on the level of methylated arginine in non-hemodialysis patients with end-stage renal disease (ESRD) and cardiovascular disease and to further explore the role of n-3 fatty acids in cardiovascular protection in patients with ESRD mechanism. METHODS: A total of 114 patients with cardiovascular disease undergoing ESRD (represented by 5 stages of chronic kidney disease) were randomly selected based on the inclusion criteria. Fifty-seven (n = 3) fatty acid interventions (experimental group) were randomly selected on a standard diet basis. The rest was given the same amount of olive oil intervention (control group). The levels of asymmetric dimethylarginine (ADMA), symmetrical dimethylarginine (L-arginine) and arginine (L-arginine) were measured by enzyme-linked immunosorbent assay (ELISA) Method was used to determine the concentrations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma n-3 fatty acids. RESULTS: No significant changes in ADMA, SDMA and L-Arginine levels were observed after 3 months of intervention with n-3 fatty acids. The levels of EPA and DHA in the serum of the study subjects were significantly higher than those before the experiment. CONCLUSIONS: n-3 fatty acids have no effect on the level of methylated arginine in non-hemodialized ESRD patients with cardiovascular disease and n-3 fatty acids did not attenuate methylated arginine in patients with ESRD complicated with cardiovascular disease Acid level and play a cardiovascular protective effect.